Fractyl Health Inc

Fractyl Health is a clinical-stage metabolic therapeutics company developing novel approaches to treat obesity and type 2 diabetes. The company's two primary product candidates are Revita, a minimally invasive endoscopic procedural therapy designed to remodel the duodenal lining to restore healthy nutrient sensing, currently in pivotal development for post-GLP-1 weight maintenance with FDA Breakthrough Device designation; and Rejuva, an AAV-based gene therapy platform targeting the pancreas for long-term remission of T2D and obesity. Revita is CE marked in the EU and UK and is investigational in the United States. Rejuva's lead candidate RJVA-001 is entering first-in-human clinical studies for inadequately controlled T2D, while RJVA-002, a dual GIP/GLP-1 gene therapy for obesity, remains in preclinical development. The company generates no revenue and is funded through equity and debt financing. Updated Aug 10, 2026